| 演何钦,白素琴,段发强.肝细胞癌患者免疫检查点抑制剂治疗期间可溶性CD27变化与生存时间的关系[J].肿瘤学杂志,2024,30(9):761-768. |
| 肝细胞癌患者免疫检查点抑制剂治疗期间可溶性CD27变化与生存时间的关系 |
| Dynamic Changes of Plasma sCD27 Levels and Survival of Hepatocellular Carcinoma Patients Receiving Immune Checkpoint Inhibitor Therapy |
| 投稿时间：2024-05-22 |
| DOI：10.11735/j.issn.1671-170X.2024.09.B008 |
|
 |
| 中文关键词: 肝细胞癌 可溶性CD27 免疫检查点抑制剂 生存 预后 |
| 英文关键词:hepatocellular carcinoma soluble CD27 immune checkpoint inhibitors survival prognosis |
| 基金项目:陕西省科学技术重点研发（2019SF-16） |
|
| 摘要点击次数: 125 |
| 全文下载次数: 48 |
| 中文摘要: |
| 摘 要：［目的］ 评估可溶性CD27（soluble CD27，sCD27）在免疫检查点抑制剂（（immune checkpoint inhibitors，ICIs）治疗期间的变化与肝细胞癌患者生存时间的关系。［方法］ 回顾性分析2017年10月至2022年3月接受ICIs方案治疗的72例肝细胞癌患者资料，在免疫治疗开始（基线）和免疫治疗第6周时通过多重荧光珠的免疫测定法检测sCD27、可溶性程序性细胞死亡蛋白1（sPD-1）和可溶性程序性死亡配体1（sPD-L1）。Δ变化值指ICIs治疗第6周时各指标与基线值的变化百分比。随访追踪患者的总生存期（overall survival，OS）、进展时间（time to progression，TTP）、无进展生存期（progression-free survival，PFS）。单因素及多因素Cox回归分析Δ-sCD27与OS、TTP、PFS的相关性。［结果］ Δ-sCD27≥2.63%的肝细胞癌患者BCLC分期更多为C/D期。Δ-sCD27与肝细胞癌患者的OS、PFS及TTP相关。 Kaplan-Meier绘图分析结果显示，Δ-sCD27≥2.63%的肝细胞癌患者OS（Log-rank χ2=14.499，P＜0.001）、PFS（Log-rank χ2=7.274，P=0.007）以及TTP（Log-rank χ2=8.605，P=0.003）更短。［结论］ Δ-sCD27≥2.63%提示晚期肝细胞癌患者ICIs治疗后生存预后较差，临床可通过监测血浆sCD27水平指导临床决策。 |
| 英文摘要: |
| Abstract：［Objective］ To analyze the relationship between change of plasma soluble CD27 (sCD27) level and the survival of patient with hepatocellular carcinoma (HCC) receiving immune checkpoint inhibitor (ICIs) therapy. ［Methods］ Clinical data of 72 HCC patients treated with ICIs from October 2017 to March 2022 were retrospectively analyzed. Plasma levels of sCD27， soluble programmed cell death protein 1 (sPD-1)， and soluble programmed cell death ligand 1 (sPD-L1) were detected by multi-bead immunoassays before (baseline) and 6 weeks after immunotherapy. Patients were followed， and the overall survival (OS)， time to progression (TTP) and progression-free survival (PFS) were documented. The correlation between the changes of sCD27 level (Δ-sCD27) and the OS， TTP and PFS of patients were analyzed by univariate and multivariate Cox regression analysis， and the prognostic value of Δ-sCD27 in HCC was analyzed by Kaplan-Meier curve. ［Results］ Univariate and multivariate Cox regression analysis showed that Δ-sCD27 was associated with PFS and TTP in HCC patients， and Δ-sCD27 was an independent predictor of OS. More HCC patients with Δ-sCD27≥2.63% had BCLC stage C/D. Kaplan-Meier curve analysis showed that HCC patients with Δ-sCD27≥2.63% had significant shorter OS (Log-rank χ2=14.499， P<0.001)， PFS (Log-rank χ2=7.274， P=0.007) and TTP (Log-rank χ2=8.605， P=0.003). ［Conclusion］ Δ-sCD27≥2.63% may indicate a poor survival prognosis of advanced HCC patients after ICIs treatment， and can evaluate the efficacy of ICIs treatment by monitoring plasma sCD27 level. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |